Researchers from the Tanenbaum group at the Hubrecht Institute have developed a new microscopy technique to observe how ...

Plasma cells (PCs) are the terminal differentiation stage of activated B cells and serve as crucial effector cells in humoral immunity. While PCs have ...

Researchers discovered a molecular timer that gets activated in the first days of pregnancy and influences when mice give ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

In animal cells, however, the major mitotic cyclin ... by which APC-substrate specificity can change at different stages of mitosis. Like other ubiquitin-protein ligases, the APC catalyses ...

While the details of the ceasefire and hostage release agreement are still hazy, Qatar Prime Minister Sheikh Mohammed bin Abdulrahman bin Jassim al-Thani said the first phase of the agreement will ...

The cease-fire deal reached Wednesday between Israel and Hamas is the first step in a process that could see the release of all hostages from the Gaza Strip and the withdrawal of the Israeli military.

The deal will take effect on Sunday, January 19, and include three phases. Photo shows Joe Biden, Antony Blinken and Kamala Harris delivering a speech at the White House. The deal, to halt Israel ...

When trastuzumab attaches to the HER2 receptor on cancer cells, it acts like a trojan horse, allowing emtansine to more effectively enter the cancer cells and kill them from within. The KATHERINE ...

The company is also developing rese-cel for several other autoimmune conditions where B-cells play a major role, including myasthenia gravis, lupus, and systemic sclerosis. Phase 1/2 trials are ...

Promising NSCLC pipeline therapies such as V940, Telisotuzumab Vedotin, QL1706, YK-029A, XL092, PRO1184, OR2805, NPX267, NI-1801, IMT-009, HS-20117, MYTX-011, HLX301, and others are under different ...

The candidate, dubbed SIM0500, targets GPRC5D, BCMA and CD3 and is already in phase 1 trials for multiple myeloma in the U.S. and China. It’s not AbbVie’s first foray into T-cell engager ...